Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 102

1.

Cost-Effectiveness of Antibody-Based Induction Therapy in Deceased Donor Kidney Transplantation in the United States.

Gharibi Z, Ayvaci MU, Hahsler M, Giacoma T, Gaston RS, Tanriover B.

Transplantation. 2016 Jul 1. [Epub ahead of print]

PMID:
27379555
2.

Novel Once-Daily Extended-Release Tacrolimus Versus Twice-Daily Tacrolimus in De Novo Kidney Transplant Recipients: Two-Year Results of Phase 3, Double-Blind, Randomized Trial.

Rostaing L, Bunnapradist S, Griny├│ JM, Ciechanowski K, Denny JE, Silva HT Jr, Budde K; Envarsus Study Group.

Am J Kidney Dis. 2016 Apr;67(4):648-59. doi: 10.1053/j.ajkd.2015.10.024. Epub 2015 Dec 22.

3.

APOL1 Genotype and Kidney Transplantation Outcomes From Deceased African American Donors.

Freedman BI, Pastan SO, Israni AK, Schladt D, Julian BA, Gautreaux MD, Hauptfeld V, Bray RA, Gebel HM, Kirk AD, Gaston RS, Rogers J, Farney AC, Orlando G, Stratta RJ, Mohan S, Ma L, Langefeld CD, Bowden DW, Hicks PJ, Palmer ND, Palanisamy A, Reeves-Daniel AM, Brown WM, Divers J.

Transplantation. 2016 Jan;100(1):194-202. doi: 10.1097/TP.0000000000000969.

PMID:
26566060
4.

Medical management of chronic kidney disease in the renal transplant recipient.

Ong SC, Gaston RS.

Curr Opin Nephrol Hypertens. 2015 Nov;24(6):587-93. doi: 10.1097/MNH.0000000000000166. Review.

PMID:
26371526
5.

Moving Beyond Minimization Trials in Kidney Transplantation.

Matas AJ, Gaston RS.

J Am Soc Nephrol. 2015 Dec;26(12):2898-901. doi: 10.1681/ASN.2015030245. Epub 2015 Apr 29. No abstract available.

PMID:
25925686
6.

Deceased donor multidrug resistance protein 1 and caveolin 1 gene variants may influence allograft survival in kidney transplantation.

Ma J, Divers J, Palmer ND, Julian BA, Israni AK, Schladt D, Pastan SO, Chattrabhuti K, Gautreaux MD, Hauptfeld V, Bray RA, Kirk AD, Brown WM, Gaston RS, Rogers J, Farney AC, Orlando G, Stratta RJ, Guan M, Palanisamy A, Reeves-Daniel AM, Bowden DW, Langefeld CD, Hicks PJ, Ma L, Freedman BI.

Kidney Int. 2015 Sep;88(3):584-92. doi: 10.1038/ki.2015.105. Epub 2015 Apr 8.

7.

AST/ASTS workshop on increasing organ donation in the United States: creating an "arc of change" from removing disincentives to testing incentives.

Salomon DR, Langnas AN, Reed AI, Bloom RD, Magee JC, Gaston RS; AST/ASTS Incentives Workshop Group (IWG).

Am J Transplant. 2015 May;15(5):1173-9. doi: 10.1111/ajt.13233. Epub 2015 Mar 31.

8.

Apolipoprotein L1 gene variants in deceased organ donors are associated with renal allograft failure.

Freedman BI, Julian BA, Pastan SO, Israni AK, Schladt D, Gautreaux MD, Hauptfeld V, Bray RA, Gebel HM, Kirk AD, Gaston RS, Rogers J, Farney AC, Orlando G, Stratta RJ, Mohan S, Ma L, Langefeld CD, Hicks PJ, Palmer ND, Adams PL, Palanisamy A, Reeves-Daniel AM, Divers J.

Am J Transplant. 2015 Jun;15(6):1615-22. doi: 10.1111/ajt.13223. Epub 2015 Mar 24.

9.

Novel once-daily extended-release tacrolimus (LCPT) versus twice-daily tacrolimus in de novo kidney transplants: one-year results of Phase III, double-blind, randomized trial.

Budde K, Bunnapradist S, Grinyo JM, Ciechanowski K, Denny JE, Silva HT, Rostaing L; Envarsus study group.

Am J Transplant. 2014 Dec;14(12):2796-806. doi: 10.1111/ajt.12955. Epub 2014 Oct 2.

10.

The high cost of organ transplant commercialism.

Matas AJ, Gaston RS.

Kidney Int. 2014 Oct;86(4):858-9. doi: 10.1038/ki.2014.184. No abstract available.

PMID:
25265958
11.

Reassessing medical risk in living kidney donors.

Gaston RS, Kumar V, Matas AJ.

J Am Soc Nephrol. 2015 May;26(5):1017-9. doi: 10.1681/ASN.2014030227. Epub 2014 Sep 25.

12.

Kidney donors at increased risk? Additional studies are needed.

Matas AJ, Woodle ES, Gaston RS, Forsythe JL, Wadstr├Âm J, Stegall MD.

Kidney Int. 2014 Sep;86(3):650. doi: 10.1038/ki.2014.146. No abstract available.

PMID:
25168503
13.

Through a glass darkly: seeking clarity in preventing late kidney transplant failure.

Stegall MD, Gaston RS, Cosio FG, Matas A.

J Am Soc Nephrol. 2015 Jan;26(1):20-9. doi: 10.1681/ASN.2014040378. Epub 2014 Aug 5. Review.

14.

Kidneys at higher risk of discard: expanding the role of dual kidney transplantation.

Tanriover B, Mohan S, Cohen DJ, Radhakrishnan J, Nickolas TL, Stone PW, Tsapepas DS, Crew RJ, Dube GK, Sandoval PR, Samstein B, Dogan E, Gaston RS, Tanriover JN, Ratner LE, Hardy MA.

Am J Transplant. 2014 Feb;14(2):404-15. doi: 10.1111/ajt.12553.

15.

Future of Medicare immunosuppressive drug coverage for kidney transplant recipients in the United States.

Tanriover B, Stone PW, Mohan S, Cohen DJ, Gaston RS.

Clin J Am Soc Nephrol. 2013 Jul;8(7):1258-66. doi: 10.2215/CJN.09440912. Epub 2013 Apr 4. Review.

16.

Report of a consensus conference on transplant program quality and surveillance.

Kasiske BL, McBride MA, Cornell DL, Gaston RS, Henry ML, Irwin FD, Israni AK, Metzler NW, Murphy KW, Reed AI, Roberts JP, Salkowski N, Snyder JJ, Sweet SC.

Am J Transplant. 2012 Aug;12(8):1988-96. doi: 10.1111/j.1600-6143.2012.04130.x. Epub 2012 Jun 8.

17.

Counseling patients for kidney transplantation: awkward conversations?

Abbott KC, Gaston RS.

Am J Transplant. 2012 Feb;12(2):273-4. doi: 10.1111/j.1600-6143.2011.03868.x. Epub 2011 Dec 7. No abstract available.

18.

Prevention of cardiovascular disease in adult recipients of kidney transplants.

Jardine AG, Gaston RS, Fellstrom BC, Holdaas H.

Lancet. 2011 Oct 15;378(9800):1419-27. doi: 10.1016/S0140-6736(11)61334-2. Review.

PMID:
22000138
19.

Our evolving understanding of late kidney allograft failure.

Gaston RS.

Curr Opin Organ Transplant. 2011 Dec;16(6):594-9. doi: 10.1097/MOT.0b013e32834c23a7. Review.

PMID:
21971511
20.

Report of a joint ESOT and AST meeting: highlights in biologic agents and transplantation.

Baan CC, Gaston RS.

Am J Transplant. 2011 Apr;11(4):681-6. doi: 10.1111/j.1600-6143.2011.03463.x.

Items per page

Supplemental Content

Loading ...
Write to the Help Desk